The A1C and ABCD of glycaemia management in type 2 diabetes: A physician's personalized approach

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 4, 2010, Pages 239-244

  Pozzilli, Paolo ^a,b   Leslie, R David ^b   Chan, Juliana ^c   De Fronzo, Ralph ^d   Monnier, Louis ^e   Raz, Itamar ^f   Del Prato, Stefano ^g  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIV MONTPELLIER   (France)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g UNIVERSITY OF PISA   (Italy)

Author keywords

Blood glucose monitoring; Diabetic complications; Glycated haemoglobin; Hypoglycaemic drugs; Therapeutic algorithm; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN DERIVATIVE; METFORMIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

AGE; ALGORITHM; BLOOD GLUCOSE MONITORING; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; HEART FAILURE; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; WEIGHT GAIN; WEIGHT REDUCTION;

AGE FACTORS; BLOOD GLUCOSE; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INDIVIDUALIZED MEDICINE; RISK ASSESSMENT;

EID: 77952778197     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1092     Document Type: Review

References (26)

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
4. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009; 52: 1219-1226.
5. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-1334.
6. Cohen RM, Franco RS, Khera PK, et al. Red cell Lifespan heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008; 112: 4284-4291.
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
9. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
10. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-885.
11. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
12. Mannucci E, Monami M, Lamanna C, et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-612.
13. Amiel SA, Dixon T, Mann R, et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254.
14. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304.
15. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.
16. Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
17. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122(6 Suppl.): S37-S50.
18. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724-733. (Pubitemid 34760182)
19. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.
20. UKPDS Group. Overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995; 44: 1249-1258.
21. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
22. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32(Suppl. 1): S1-S201, http://www.diabetes.ca/files/cpg2008/cpg-2008.pdf.
23. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
24. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
25. National Collaborating Centre for Chronic Conditions. Type 2 diabetes. National clinical guidelines for management in primary and secondary care (update). http://www.nice.org.uk/nicemedia/pdf/CG66diabetesfullguideline.pdf.
26. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents. NICE short clinical guideline 87. Issue date: May 2009; http://www.nice.org.uk/nicemedia/pdf/CG87ShortGuideline.pdf.